Biologic Product Naming: US FDA Sticks With Suffixes ‘Devoid Of Meaning’
Executive Summary
Final guidance adds new factors for biosimilar and innovative sponsors to consider in developing distinguishable suffixes for nonproprietary names but FDA is unswayed by calls for meaningful suffixes derived from license holder’s name; timing of retrospective application to previously approved products remains in question.
You may also be interested in...
FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi
Third biosimilar approved in US brings another iteration of FDA thinking on labeling and naming; etanercept-szzs, which references Amgen's Enbrel, suggests agency might be backtracking on its suffix policy.
BLAs More Appealing As 'Transition' NDAs, ANDAs Set To Lose Exclusivity
Certain protein products approved under FD&C Act before March 23, 2020 would lose their remaining non- orphan exclusivity, and would not qualify for 12-year biologic exclusivity.
FDA Biosimilar Naming Proposal Pits Providers, Patients Against Insurers, Pharmacies
Suffix-based, distinguishable names cheered by physicians and patient advocacy groups as enhancing patient safety; payers and pharmacists object, saying plan adds unneeded complexity and will require expensive overhauls in databases and operating systems.